STAT3 and gastric cancer: Considering the preliminary success of CAR-T-cell therapy in treating gastric cancer [107], future strategies might include employing genetic engineering to knock out or silence the STAT3 gene in CAR-T cells before they are reinfused into patients with gastric cancer.